Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases: New Insights and Future Directions
Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases: New Insights and Future Directions
复制标题
DOI：
10.1021/jm500907a
复制
发表时间：
2015-03-12
影响因子：
7.3
通讯作者：
Ottana, Rosaria
中科院分区：
文献类型：
--
作者：
Maccari, Rosanna;Ottana, Rosaria
醛糖还原酶 (AR) 是一种醛酮还原酶，作为与糖尿病相关慢性并发症的发病机制至关重要的酶，已被广泛研究。最近确定 AR 还充当某些氧化和炎症信号传导途径的关键介质，这些信号传导途径参与不同人类病理学的发展，例如心血管疾病、败血症和癌症。这些发现重新激发了人们对寻找新的 AR 抑制剂 (ARI) 的兴趣，这些抑制剂作为潜在的治疗药物具有改进的特性。在这篇综述中，讨论了该领域的最新进展以及开发 ARI 的有前景的未来方向。
Aldose reductase (AR) is an aldo-keto reductase that has been widely investigated as an enzyme crucially involved in the pathogenesis of chronic complications associated with diabetes mellitus. Recently it was established that AR also acts as a key mediator of certain oxidative and inflammatory signaling pathways that are involved in the development of different human pathologies, such as cardiovascular disorders, sepsis, and cancer. These findings have renewed interest in the search for new AR inhibitors (ARIs) with improved profiles as potential therapeutic agents. In this review, recent advances in the field and promising future directions for developing ARIs are discussed.